Aldevron, LLC entered into an agreement to acquire global exclusive license for Codex® HiCap RNA Polymerase from Codexis, Inc. (NasdaqGS:CDXS) on December 13, 2023. Under the terms of the deal, Aldevron will receive global manufacturing and commercialization rights to the Codex® HiCap RNA Polymerase and Codexis will receive payments for near-term technical milestones, along with commercial milestones and sales-based royalties.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.62 USD | +4.32% | -7.65% | +18.69% |
May. 02 | Earnings Flash (CDXS) CODEXIS Posts Q1 Revenue $17.1M, vs. Street Est of $13.3M | MT |
May. 02 | Transcript : Codexis, Inc., Q1 2024 Earnings Call, May 02, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.69% | 255M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- CDXS Stock
- News Codexis, Inc.
- Aldevron, LLC entered into an agreement to acquire global exclusive license for Codex® HiCap RNA Polymerase from Codexis, Inc..